Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab vs docetaxel in previously treated NSCLC after PD-(L)1 inhibitor and platinum chemotherapy
jRCT2080224544Phase 3Completed
- Start
- Feb 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing canakinumab with docetaxel (2 arms). Primary endpoint: Overall survival. Started Feb 2019; status: completed.
02
Drugs
canakinumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224544.